THE UNSTABLE HEMOGLOBINS: SOME GENETIC ASPECTS
Wajcman H1,*, Galacteros F2
*Corresponding Author: Dr. Henri Wajcman, INSERM U 468 and Service de Biochimie, Hôpital Henri Mondor AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France
page: 3

UNSTABLE HEMOGLOBINS CARRIED BY THE α GENE

When the amount of α chains is insufficient to bind all the available β chains, the β chains in excess associate into homologous β4 tetramers named Hb H, which behave as a typically unstable Hb. In the case of unstable variants affecting the a chain, the situation is complex due to the presence of four a genes in normal individuals.
An unstable a chain variant, when present in the het­erozygous state, usually leads to a heterozygous α+- thal phenotype, which is similar to that resulting from nondele­tional α-thal mutations. For example, Hb Bronte [α93 (FG5)Val→Gly (α2)] [35], which is the α chain equiva­lent of Hb Nottingham [β98(FG5)Val→Gly] [36], is ex­pressed at α level of 6%. When present in the simple het­erozygous state, such variants usually have very mild, or no apparent, hematological effects. Heterozygous carriers are usually identified by chance, when α Hb screening is performed in α population at-risk for the frequent hemo­globinopathies. They are suspected when α band that may correspond to an α chain variant, present at α very low level, is observed by isoelectrofocusing (IEF) or by cation exchange HPLC. When the substitutions are electropho­retically neutral they may pass unnoticed. Recently, sev­eral variants leading to borderline RBC parameters were identified by electrospray ionization mass spectrometry (ESI-MS). The example concerning Hb Esch, an α1 mu­tant [37], which amounted to less than 5% and resulted from the duplication of the 12 nucleotides corresponding to codons 65 through 68, is shown in Fig. 3.


When the carriers are homozygous, or compound het­erozygous for another α chain abnormality, they may suf­fer from a severe hemolytic anemia, with the presence of α low percentage of Hb H. Having no deleterious conse­quence in the heterozygous state, they may be common in some populations, and thus found in several members of α family, explaining the possibility for homozygous cases. Hb Taybe [α1; 38 or 39 (Thr→0)] illustrates this situation: the variant was initially found in an Arabic family from Israel where the proband, who was homozygous, suffered from a severe hemolytic anemia with Hb H and some de­gree of dyserythropoiesis [38-40]. This variant was later found in several families belonging to this population, and also in other, completely different ethnic groups, as for example in China. Hb Sallanches [α104(G11)Cys→Tyr (α2)], was initially described in France in α homozygous patient with hemolytic anemia, while it is totally silent in the heterozygous state [41]. It was recently found to be a cause of nondeletional α-thal in Pakistan, leading also to Hb H when associated with another a chain abnormality [42,43]. The group of unstable a chain variants due to protein elongation at their C-terminal, such as Hbs Con­stant Spring or Paksé, are considered as a frequent and classic cause of nondeletional α-thal in Southeast Asia. Homozygous cases of Hb Constant Spring suffer from α chronic macrocytic hemolytic anemia with traces of Hb H. A few similar examples of unstable a chain variants with elongated chains were found in Greece, likely as the result of an intensive search for thalassemic mutations in this population.
It may be important to know about the possibility of the presence of such unstable a chain variants, even in populations free of thalassemias, since today, with the large mobility of people, unexpected associated cases may occur. For example, a severe neonatal anemia was recently reported in twins born to an Irish-Scottish and Asian cou­ple. Hemoglobin studies showed that the father was het­erozygous for Hb Dartmouth [α66(E15)Leu→Pro (α2)] α silent unstable variant, while the mother was heterozygous for a Southeast Asian α0-thal [44].
In the past few years, the diagnosis of some unstable α chain variants was difficult when the structural abnor­mality resulted in α disturbed protein folding and in α defective subunit assembly. Paradoxical biosynthetic data with a β-thalassemic-like biosynthetic ratio after 1 hour of incubation, were then observed but not after short incuba­tion times. Hb Questembert [α131(H14)Ser→Pro] [45,46] and Hb Ann Arbor [α80(F1)Leu→Arg] [47] illustrate this situation. These kinds of problems should easily be solved today by the use of ESI-MS, which would readily show that the abnormality is carried by an α chain, and by se­quencing the α genes to find the abnormality.
Due to the high frequency of the 3.7 kb deletion, the possibility exists for the mutation to be carried by the remaining recombinant α2α1 gene, which product nor­mally amounts to 30-35% of the total α chains. Under these circumstances, the level of expression of an unstable a chain variant will become similar to that of a stable α1 mutation. To solve this problem, the recombinant α2α1 gene, which by PCR is usually amplified together with the α1 gene, should be isolated by electrophoresis before sequencing [48].




Number 27
VOL. 27 (2), 2024
Number 27
VOL. 27 (1), 2024
Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006